Objective: Our objective is to show the superiority of the membrane selection and connected energy
dose fixed via personal sensing.
Method: Hyperthermia in oncology involves heating malignant cells and causing thermal damage in
an attempt to destroy them. This could be immediate (necrotic) cell-distortion and ignite natural cell
elimination, like apoptosis or autophagy.
Two concepts determine the dose of hyperthermia: (1) isothermal tumour heating, homogeneous
tumour temperature, which is used for necrosis based cumulative equivalent minutes (CEM), and (2)
inhomogeneous heating of the tumour following the heterogeneity of the lesion itself. The
personalized dosing used by oncothermia is heterogenic, it selects the membrane rafts of malignant
cells that sense temperature on a cellular level targeting the nano-clusters of transmembrane
proteins. The method uses the standard specific energy dosing controlled by personal sensing of the
treated patient maintaining homeostatic control through gradual step-up heating process.
Results: The nano excitation is thermal (fits to Arrhenius plot), and acts directly on the membrane of
malignant cells. The homeostatic physiology reactions do not suppress the effective hyperthermia
action with this heating. The stress reactions could be more regulated, the vasocontraction and
vasodilatation effects roughly compensate each other. This allows a clear measurability of the dose of
the treatment: instead of the temperature based cumulative equivalent minutes (CEM) it uses
absorbed energy controlled by the RF-circuit. Due to the small mass of targets the applied power is
low, the energy-sink surface cooling is fixed to homeostasis ensuring the accuracy of the energy-dose
and improving the safety of the hyperthermia method.
Conclusion: The nanoselection of malignant cells via oncothermia allows us to return to the dosing
“gold standard,” which is also applied in radiotherapy. This energy-based dose is personalised with
accurate step-up heating taking the wash-out time and the personal sensing of the patient into
Dr. Gyula Peter Szigeti
Innovation Center, Semmelweis University, Hungary.
Dr. Oliver Szasz
Department of Biotechnics, St. Istvan University, Hungary.
Prof. Dr Gabriella Hegyi
Department of Complementary Medicine, Medical School, Pecs University, Hungary.
View Book :- https://bp.bookpi.org/index.php/bpi/catalog/book/232